Share
array:24 [ "pii" => "S2254887417300334" "issn" => "22548874" "doi" => "10.1016/j.rceng.2017.02.004" "estado" => "S300" "fechaPublicacion" => "2017-05-01" "aid" => "1373" "copyright" => "Elsevier España, S.L.U. and Sociedad Española de Medicina Interna (SEMI)" "copyrightAnyo" => "2016" "documento" => "article" "crossmark" => 1 "subdocumento" => "fla" "cita" => "Rev Clin Esp. 2017;217:201-6" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:2 [ "total" => 1 "PDF" => 1 ] "Traduccion" => array:1 [ "es" => array:19 [ "pii" => "S0014256517300607" "issn" => "00142565" "doi" => "10.1016/j.rce.2017.02.005" "estado" => "S300" "fechaPublicacion" => "2017-05-01" "aid" => "1373" "copyright" => "Elsevier España, S.L.U. and Sociedad Española de Medicina Interna (SEMI)" "documento" => "article" "crossmark" => 1 "subdocumento" => "fla" "cita" => "Rev Clin Esp. 2017;217:201-6" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:2 [ "total" => 48 "formatos" => array:2 [ "HTML" => 31 "PDF" => 17 ] ] "es" => array:13 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Original</span>" "titulo" => "Eficacia y seguridad de una pauta basal plus con insulina glargina e insulina glulisina en pacientes ancianos de alto riesgo cardiovascular con diabetes mellitus tipo 2" "tienePdf" => "es" "tieneTextoCompleto" => "es" "tieneResumen" => array:2 [ 0 => "es" 1 => "en" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "201" "paginaFinal" => "206" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Safety and efficacy of a basal-plus regimen with insulin glargine and insulin glulisine for elderly patients with high cardiovascular risk and type 2 diabetes mellitus" ] ] "contieneResumen" => array:2 [ "es" => true "en" => true ] "contieneTextoCompleto" => array:1 [ "es" => true ] "contienePdf" => array:1 [ "es" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0005" "etiqueta" => "Figura 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 1200 "Ancho" => 1629 "Tamanyo" => 112343 ] ] "descripcion" => array:1 [ "es" => "<p id="spar0045" class="elsevierStyleSimplePara elsevierViewall">Media de los 3 perfiles de autoanálisis de glucemia capilar.</p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "R. Gómez-Huelgas, J. Sabán-Ruiz, F.J. García-Román, N. Quintela-Fernández, J.M. Seguí-Ripoll, M.V. Bonilla-Hernández, G. Romero-Meliá" "autores" => array:7 [ 0 => array:2 [ "nombre" => "R." "apellidos" => "Gómez-Huelgas" ] 1 => array:2 [ "nombre" => "J." "apellidos" => "Sabán-Ruiz" ] 2 => array:2 [ "nombre" => "F.J." "apellidos" => "García-Román" ] 3 => array:2 [ "nombre" => "N." "apellidos" => "Quintela-Fernández" ] 4 => array:2 [ "nombre" => "J.M." "apellidos" => "Seguí-Ripoll" ] 5 => array:2 [ "nombre" => "M.V." "apellidos" => "Bonilla-Hernández" ] 6 => array:2 [ "nombre" => "G." "apellidos" => "Romero-Meliá" ] ] ] ] ] "idiomaDefecto" => "es" "Traduccion" => array:1 [ "en" => array:9 [ "pii" => "S2254887417300334" "doi" => "10.1016/j.rceng.2017.02.004" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2254887417300334?idApp=WRCEE" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0014256517300607?idApp=WRCEE" "url" => "/00142565/0000021700000004/v3_201705221132/S0014256517300607/v3_201705221132/es/main.assets" ] ] "itemSiguiente" => array:19 [ "pii" => "S225488741730036X" "issn" => "22548874" "doi" => "10.1016/j.rceng.2017.02.006" "estado" => "S300" "fechaPublicacion" => "2017-05-01" "aid" => "1376" "copyright" => "Elsevier España, S.L.U. and Sociedad Española de Medicina Interna (SEMI)" "documento" => "article" "crossmark" => 1 "subdocumento" => "fla" "cita" => "Rev Clin Esp. 2017;217:212-21" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:2 [ "total" => 1 "PDF" => 1 ] "en" => array:13 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Special Article</span>" "titulo" => "Commitment to quality of the Spanish scientific societies" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => array:2 [ 0 => "en" 1 => "es" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "212" "paginaFinal" => "221" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Compromiso por la calidad de las sociedades científicas en España" ] ] "contieneResumen" => array:2 [ "en" => true "es" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0005" "etiqueta" => "Figure 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 889 "Ancho" => 1670 "Tamanyo" => 170289 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0015" class="elsevierStyleSimplePara elsevierViewall">Methodology for the preliminary selection of “do not do” recommendations.</p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "J. García-Alegría, S. Vázquez-Fernández del Pozo, F. Salcedo-Fernández, J.M. García-Lechuz Moya, G. Andrés Zaragoza-Gaynor, M. López-Orive, S. García-San Jose, P. Casado-Durández" "autores" => array:8 [ 0 => array:2 [ "nombre" => "J." "apellidos" => "García-Alegría" ] 1 => array:2 [ "nombre" => "S." "apellidos" => "Vázquez-Fernández del Pozo" ] 2 => array:2 [ "nombre" => "F." "apellidos" => "Salcedo-Fernández" ] 3 => array:2 [ "nombre" => "J.M." "apellidos" => "García-Lechuz Moya" ] 4 => array:2 [ "nombre" => "G." "apellidos" => "Andrés Zaragoza-Gaynor" ] 5 => array:2 [ "nombre" => "M." "apellidos" => "López-Orive" ] 6 => array:2 [ "nombre" => "S." "apellidos" => "García-San Jose" ] 7 => array:2 [ "nombre" => "P." "apellidos" => "Casado-Durández" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "S0014256517300656" "doi" => "10.1016/j.rce.2017.02.008" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0014256517300656?idApp=WRCEE" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S225488741730036X?idApp=WRCEE" "url" => "/22548874/0000021700000004/v1_201704280917/S225488741730036X/v1_201704280917/en/main.assets" ] "itemAnterior" => array:19 [ "pii" => "S2254887417300103" "issn" => "22548874" "doi" => "10.1016/j.rceng.2016.12.007" "estado" => "S300" "fechaPublicacion" => "2017-05-01" "aid" => "1349" "copyright" => "Elsevier España, S.L.U. and Sociedad Española de Medicina Interna (SEMI)" "documento" => "article" "crossmark" => 1 "subdocumento" => "fla" "cita" => "Rev Clin Esp. 2017;217:193-200" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:2 [ "total" => 2 "PDF" => 2 ] "en" => array:13 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Original article</span>" "titulo" => "Healthcare resources and needs in anticoagulant therapy for patients with nonvalvular atrial fibrillation. SAMOA Study" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => array:2 [ 0 => "en" 1 => "es" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "193" "paginaFinal" => "200" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Recursos y necesidades asistenciales en el tratamiento anticoagulante de los pacientes con fibrilación auricular no valvular. Estudio SAMOA" ] ] "contieneResumen" => array:2 [ "en" => true "es" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0010" "etiqueta" => "Figure 2" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr2.jpeg" "Alto" => 1476 "Ancho" => 1633 "Tamanyo" => 123830 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0055" class="elsevierStyleSimplePara elsevierViewall">Main barriers in the management of patients undergoing anticoagulant therapy.</p> <p id="spar0060" class="elsevierStyleSimplePara elsevierViewall">Abbreviations: SC: specialized care; PC: primary care.</p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "V. Barrios, M.I. Egocheaga-Cabello, J. Gállego-Culleré, E. Ignacio-García, L. Manzano-Espinosa, A. Martín-Martínez, J. Mateo-Arranz, J. Polo-García, D. Vargas-Ortega" "autores" => array:9 [ 0 => array:2 [ "nombre" => "V." "apellidos" => "Barrios" ] 1 => array:2 [ "nombre" => "M.I." "apellidos" => "Egocheaga-Cabello" ] 2 => array:2 [ "nombre" => "J." "apellidos" => "Gállego-Culleré" ] 3 => array:2 [ "nombre" => "E." "apellidos" => "Ignacio-García" ] 4 => array:2 [ "nombre" => "L." "apellidos" => "Manzano-Espinosa" ] 5 => array:2 [ "nombre" => "A." "apellidos" => "Martín-Martínez" ] 6 => array:2 [ "nombre" => "J." "apellidos" => "Mateo-Arranz" ] 7 => array:2 [ "nombre" => "J." "apellidos" => "Polo-García" ] 8 => array:2 [ "nombre" => "D." "apellidos" => "Vargas-Ortega" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "S0014256517300115" "doi" => "10.1016/j.rce.2016.12.011" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0014256517300115?idApp=WRCEE" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2254887417300103?idApp=WRCEE" "url" => "/22548874/0000021700000004/v1_201704280917/S2254887417300103/v1_201704280917/en/main.assets" ] "en" => array:21 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Original article</span>" "titulo" => "Safety and efficacy of a basal-plus regimen with insulin glargine and insulin glulisine for elderly patients with high cardiovascular risk and type 2 diabetes mellitus" "tieneTextoCompleto" => true "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "201" "paginaFinal" => "206" ] ] "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "R. Gómez-Huelgas, J. Sabán-Ruiz, F.J. García-Román, N. Quintela-Fernández, J.M. Seguí-Ripoll, M.V. Bonilla-Hernández, G. Romero-Meliá" "autores" => array:7 [ 0 => array:4 [ "nombre" => "R." "apellidos" => "Gómez-Huelgas" "email" => array:1 [ 0 => "ricardogomezhuelgas@hotmail.com" ] "referencia" => array:2 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] 1 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">*</span>" "identificador" => "cor0005" ] ] ] 1 => array:3 [ "nombre" => "J." "apellidos" => "Sabán-Ruiz" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "aff0010" ] ] ] 2 => array:3 [ "nombre" => "F.J." "apellidos" => "García-Román" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">c</span>" "identificador" => "aff0015" ] ] ] 3 => array:3 [ "nombre" => "N." "apellidos" => "Quintela-Fernández" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">d</span>" "identificador" => "aff0020" ] ] ] 4 => array:3 [ "nombre" => "J.M." "apellidos" => "Seguí-Ripoll" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">e</span>" "identificador" => "aff0025" ] ] ] 5 => array:3 [ "nombre" => "M.V." "apellidos" => "Bonilla-Hernández" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">f</span>" "identificador" => "aff0030" ] ] ] 6 => array:3 [ "nombre" => "G." "apellidos" => "Romero-Meliá" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">g</span>" "identificador" => "aff0035" ] ] ] ] "afiliaciones" => array:7 [ 0 => array:3 [ "entidad" => "Servicio de Medicina Interna, Hospital Regional Universitario de Málaga, FIMABIS, Málaga, Spain" "etiqueta" => "a" "identificador" => "aff0005" ] 1 => array:3 [ "entidad" => "Unidad de Endotelio y Medicina Cardiometabólica, Hospital Universitario Ramón y Cajal, Madrid, Spain" "etiqueta" => "b" "identificador" => "aff0010" ] 2 => array:3 [ "entidad" => "Residencia Los Almendros, Murcia, Spain" "etiqueta" => "c" "identificador" => "aff0015" ] 3 => array:3 [ "entidad" => "Medicina Interna, Clínica Dra. Niurka Quintela Fernández, Santa Cruz de Tenerife, Tenerife, Spain" "etiqueta" => "d" "identificador" => "aff0020" ] 4 => array:3 [ "entidad" => "Hospital San Juan, Alicante, Spain" "etiqueta" => "e" "identificador" => "aff0025" ] 5 => array:3 [ "entidad" => "Hospital Reina Sofía, Tudela, Navarra, Spain" "etiqueta" => "f" "identificador" => "aff0030" ] 6 => array:3 [ "entidad" => "Departamento Médico, Sanofi, Barcelona, Spain" "etiqueta" => "g" "identificador" => "aff0035" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor0005" "etiqueta" => "⁎" "correspondencia" => "Corresponding author." ] ] ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Eficacia y seguridad de una pauta basal plus con insulina glargina e insulina glulisina en pacientes ancianos de alto riesgo cardiovascular con diabetes mellitus tipo 2" ] ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0005" "etiqueta" => "Figure 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 1190 "Ancho" => 1658 "Tamanyo" => 107902 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0045" class="elsevierStyleSimplePara elsevierViewall">Average of the 3 self-analysis profiles of capillary blood glucose.</p>" ] ] ] "textoCompleto" => "<span class="elsevierStyleSections"><span id="sec0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0065">Background</span><p id="par0005" class="elsevierStylePara elsevierViewall">Patients with type 2 diabetes mellitus (DM2) have a high risk of presenting cardiovascular diseases.<a class="elsevierStyleCrossRef" href="#bib0115"><span class="elsevierStyleSup">1</span></a> Moreover, the aging of the population is causing a marked increase in the prevalence of DM2 among elderly patients.<a class="elsevierStyleCrossRef" href="#bib0120"><span class="elsevierStyleSup">2</span></a></p><p id="par0010" class="elsevierStylePara elsevierViewall">Elderly patients with diabetes present certain characteristics, such as high comorbidity, a shorter life expectancy, geriatric syndromes and polypharmacy, which determine the treatment.<a class="elsevierStyleCrossRef" href="#bib0125"><span class="elsevierStyleSup">3</span></a> In this context, the Veterans Affairs Diabetes Trial (VADT),<a class="elsevierStyleCrossRef" href="#bib0130"><span class="elsevierStyleSup">4</span></a> the Action to Control Cardiovascular Risk in Diabetes (ACCORD)<a class="elsevierStyleCrossRef" href="#bib0135"><span class="elsevierStyleSup">5</span></a> and the Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation (ADVANCE)<a class="elsevierStyleCrossRef" href="#bib0140"><span class="elsevierStyleSup">6</span></a> studies have shown that strict metabolic control in middle-aged patients (60–66 years), with long-standing DM2 (8–10 years) and high vascular risk, does not reduce the associated cardiovascular morbidity and mortality and could result in an increase in mortality and the number of hypoglycemic episodes. For this reason, glycemic control objectives for elderly individuals should be individualized, based on each patient's characteristics.<a class="elsevierStyleCrossRef" href="#bib0145"><span class="elsevierStyleSup">7</span></a> Although there is currently no agreement on the glycated hemoglobin (HbA1c) objective for elderly patients, a value between 7% and 9% is considered acceptable. The European Diabetes Working Party for Older People 2011<a class="elsevierStyleCrossRef" href="#bib0150"><span class="elsevierStyleSup">8</span></a> and the Spanish Consensus for the Treatment of DM2 in the Elderly<a class="elsevierStyleCrossRef" href="#bib0120"><span class="elsevierStyleSup">2</span></a> recommend an HbA1c objective of 7–7.5% for the elderly without complications and 7.6–8.5% for frail elderly patients. The American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) consider an HbA1c value between 7.5% and 8.5% as acceptable, based on life expectancy, morbidity and polypharmacy, among other variables.<a class="elsevierStyleCrossRef" href="#bib0155"><span class="elsevierStyleSup">9</span></a></p><p id="par0015" class="elsevierStylePara elsevierViewall">The current recommendations for antidiabetic treatment in elderly patients is based on clinical judgment, because there is very little scientific evidence on the risk-benefit ratio of intensive treatment and its long-term administration.<a class="elsevierStyleCrossRef" href="#bib0160"><span class="elsevierStyleSup">10</span></a></p><p id="par0020" class="elsevierStylePara elsevierViewall">For elderly patients who require insulin, the safest option is the introduction of basal insulin, typically combined with 1 or 2 oral diabetes drugs (ODD). If the patient does not achieve the HbA1c objective with basal insulin, the current guidelines<a class="elsevierStyleCrossRefs" href="#bib0120"><span class="elsevierStyleSup">2,8,9</span></a> recommend intensifying the treatment by adding a single dose of prandial insulin before the main meal, which is the meal that causes the greatest increase in postprandial blood glucose. This therapeutic strategy, which is known as basal-plus (BP) therapy, attempts to imitate the physiological profile and promote a gradual approach toward the basal-bolus regimen.<a class="elsevierStyleCrossRef" href="#bib0120"><span class="elsevierStyleSup">2</span></a> However, there is little evidence on the use of BP therapy in elderly patients with high vascular risk in clinical practice. This observational study was therefore conducted to evaluate the safety and efficacy of this BP therapy.</p></span><span id="sec0010" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0070">Patients and methods</span><p id="par0025" class="elsevierStylePara elsevierViewall">An observational, retrospective study was conducted in 21 internal medicine departments in centers distributed throughout Spain. The study was conducted according to the Declaration of Helsinki and current legislation. The study was evaluated and approved by the Regional Committee of Galicia (SERGAS), and all patients granted their written informed consent.</p><span id="sec0015" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0075">Patient selection</span><p id="par0030" class="elsevierStylePara elsevierViewall">We included patients 65 years of age or older with DM2 and a diagnosis of cardiovascular disease (ischemic heart disease, acute stroke or peripheral arterial disease) or a high cardiovascular risk. The latter condition was defined as the presence of at least 2 of the following risk factors: active tobacco consumption, microalbuminuria (30–300<span class="elsevierStyleHsp" style=""></span>mg/24<span class="elsevierStyleHsp" style=""></span>h), macroalbuminuria (>300<span class="elsevierStyleHsp" style=""></span>mg/24<span class="elsevierStyleHsp" style=""></span>h), renal failure (creatinine<span class="elsevierStyleHsp" style=""></span>><span class="elsevierStyleHsp" style=""></span>1.4<span class="elsevierStyleHsp" style=""></span>mg/dL in women and >1.5<span class="elsevierStyleHsp" style=""></span>mg/dL in men or a glomerular filtration rate <45<span class="elsevierStyleHsp" style=""></span>mL/min/1.73<span class="elsevierStyleHsp" style=""></span>m<span class="elsevierStyleSup">2</span>), neuropathy or diabetic retinopathy, heart failure, arterial hypertension, obesity (body mass index ≥30<span class="elsevierStyleHsp" style=""></span>kg/m<span class="elsevierStyleSup">2</span>) and dyslipidemia. Furthermore, the patients had to be undergoing treatment with a BP regimen, with insulin glargine administered once a day and insulin glulisine at lunch (the main meal), for a minimum of 4 months and a maximum of 1-year before enrolling in the study, in combination or not with ODD. We excluded patients with other types of diabetes (type 1 DM, latent autoimmune diabetes in adults, steroid diabetes or pancreatic diabetes), mental disease or terminal-phase disease.</p></span><span id="sec0020" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0080">Patient evaluation</span><p id="par0035" class="elsevierStylePara elsevierViewall">The information was collected retrospectively at the start of treatment with the BP regimen and in the clinical visit during which the patients were enrolled (at least 4 months after starting the BP regimen). The information collected at both times consisted of demographic and anthropometric data, medical history and glucose control values (HbA1c and capillary blood glucose self-monitoring profile). We recorded the diabetic treatment-related data (ODD, type of insulin and total daily dose of insulin), adverse reactions, number of hypoglycemic episodes reported during the month after the BP regimen was introduced and the type of diabetes education, if received. This last point was assessed at the same time as the blood extraction for the HbA1c reading by asking whether the patient had received diabetes education. The response could be yes or no. If yes, the following options were selected: “Exercise, self-analysis of capillary blood glucose (implementation/interpretation), self-adjustment of rapid insulin dose and correct use of the injection device”. We also documented the number of patients who were checked; in other words, who achieved an HbA1c value of 7.5–8%.<a class="elsevierStyleCrossRefs" href="#bib0120"><span class="elsevierStyleSup">2,8,9</span></a></p><p id="par0040" class="elsevierStylePara elsevierViewall">Asymptomatic hypoglycemia was defined as an asymptomatic episode of hypoglycemia, associated with a capillary blood glucose value <70<span class="elsevierStyleHsp" style=""></span>mg/dL. Symptomatic hypoglycemia was defined as the presence of hypoglycemic symptoms, along with the detection of a capillary blood glucose value <70<span class="elsevierStyleHsp" style=""></span>mg/dL. Severe symptomatic hypoglycemia was established as a hypoglycemic episode whose recovery depended on the help of another individual who administered carbohydrates, glucagon or other measures due to a state of confusion or loss of consciousness in the patient. Lastly, nocturnal hypoglycemia was that which occurred when the patient was sleeping, after going to bed and before waking up in the morning.</p></span><span id="sec0025" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0085">Statistical analysis</span><p id="par0045" class="elsevierStylePara elsevierViewall">A descriptive analysis of the study variables was conducted, using measures of centralization and dispersion for quantitative variables (mean, median, standard deviation [SD] and interquartile range [IQR]) and frequencies and percentages for the qualitative variables. Two logistic regression analyses were performed to determine the patient profile with the best HbA1c control and the factors associated with the presence of hypoglycemia. A <span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span>≤<span class="elsevierStyleHsp" style=""></span>.05 was considered a statistically significant difference. All analyses were performed using the SPSS (version 21.0, Chicago, USA) statistical program.</p></span></span><span id="sec0030" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0090">Results</span><span id="sec0035" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0095">Patients</span><p id="par0050" class="elsevierStylePara elsevierViewall">From June 2013 to July 2014, 200 patients were included, 2 of whom were excluded for being younger than 65. A total of 198 patients were evaluable; the mean age was 74<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>6.4 years, and the majority were men (52%). <a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a> shows a summary of the demographic and clinical characteristics of the study population.</p><elsevierMultimedia ident="tbl0005"></elsevierMultimedia></span><span id="sec0040" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0100">Treatment for diabetes, diabetes education and therapeutic approach</span><p id="par0055" class="elsevierStylePara elsevierViewall">At the time of their inclusion, all patients were undergoing treatment with insulin glargine (median dosage [IQR], 24 [16–34]<span class="elsevierStyleHsp" style=""></span>IU/day) and insulin glulisine (6 [5–8]<span class="elsevierStyleHsp" style=""></span>IU/day). At the same time, 144 (72.7%) patients were treated with at least one ODD: metformin (88.2%), sulfonylurea (6.3%), dipeptidildipeptidasa-4 inhibitors (3.5%) and glinides (2.1%). Some 76.8% of the patients took glulisine during lunch, and the others took the glulisine dose before breakfast or dinner.</p><p id="par0060" class="elsevierStylePara elsevierViewall">At the inclusion visit, 156 (78.8%) patients indicated that they had participated in some diabetes education activity: diet control for 143 patients (91.7%), exercise for 131 (84%), capillary blood glucose self-analysis (implementation/interpretation) for 83 (53.2%), care and/or self-hygiene for 72 (46.2%), correct use of the injection device for 53 (34%), self-adjustment of the insulin dose for 46 (29.5%) and other types for 3 (1.9%).</p></span><span id="sec0045" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0105">Changes in glycated hemoglobin and capillary blood glucose</span><p id="par0065" class="elsevierStylePara elsevierViewall">We observed a 1.32% reduction in the mean HbA1c levels, going from 9% (±1.5) at the time the BP regimen was started to 7.7±1.1% (<span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span><<span class="elsevierStyleHsp" style=""></span>.001). Thus, 44 (23.9%) patients had achieved the metabolic control established for this patient group (HbA1c, 7.5–8%) at the study's inclusion visit. Based on the logistic regression analysis, adjusted for the initial HbA1c level, the patients with better HbA1c control were those who stated having undergone diabetes education based on the self-analysis of capillary blood glucose (OR, 3.5; 95% CI 1.4–8.5, <span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>.005) and who had a more advanced age at the diagnosis of the DM2 (OR, 1.1; 95% CI 1.1–1.1).</p><p id="par0070" class="elsevierStylePara elsevierViewall">We also observed a significant reduction in mean plasma blood glucose levels under fasting conditions from the start of the BP strategy to at least 4 months of treatment (190.6<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>73.2<span class="elsevierStyleHsp" style=""></span>mg/dL vs. 138.9<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>38.2<span class="elsevierStyleHsp" style=""></span>mg/dL; <span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span><<span class="elsevierStyleHsp" style=""></span>.001). With regard to the last 3 self-analysis profiles of capillary blood glucose, we obtained lower mean values under fasting conditions and in the mornings; however, we obtained similar values for the measurements performed 2<span class="elsevierStyleHsp" style=""></span>h after lunch. The mean values for the 3 capillary blood glucose self-analysis profiles at the various times of day are listed in <a class="elsevierStyleCrossRef" href="#fig0005">Fig. 1</a>.</p><elsevierMultimedia ident="fig0005"></elsevierMultimedia></span><span id="sec0050" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0110">Adverse events</span><p id="par0075" class="elsevierStylePara elsevierViewall">During the study, 35 (17.7%) patients presented a total of 62 hypoglycemic episodes (<a class="elsevierStyleCrossRef" href="#tbl0010">Table 2</a>). Only 2 cases (1%) of severe hypoglycemia were detected (one of them nocturnal).</p><elsevierMultimedia ident="tbl0010"></elsevierMultimedia></span></span><span id="sec0055" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0115">Discussion</span><p id="par0080" class="elsevierStylePara elsevierViewall">The results of this study show that the administration of a BP regimen to patients 65 years or older with DM2 and high cardiovascular risk, in real clinical conditions, is associated with improved glycemic control, obtaining a mean HbA1c reduction of 1.32%. However, only 24% of this patient group achieved HbA1c levels of 7.5–8%, the recommended therapeutic range for these cases.<a class="elsevierStyleCrossRefs" href="#bib0120"><span class="elsevierStyleSup">2,8,9</span></a></p><p id="par0085" class="elsevierStylePara elsevierViewall">Several studies have evaluated the beneficial effect of the BP strategy. The results of the Proof of Concept<a class="elsevierStyleCrossRef" href="#bib0165"><span class="elsevierStyleSup">11</span></a> and Oral Plus Apidra and Lantus studies<a class="elsevierStyleCrossRef" href="#bib0170"><span class="elsevierStyleSup">12</span></a> support a simplified approach for the progressive intensification of treatment with prandial insulin. Both studies were randomized and open and included a broad group of patients with DM2 that was poorly controlled with basal insulin and ODD, for whom treatment intensification was achieved through dose titration of the insulin glulisine for 6 months<a class="elsevierStyleCrossRef" href="#bib0165"><span class="elsevierStyleSup">11</span></a> or with the addition of a single bolus of insulin glulisine.<a class="elsevierStyleCrossRef" href="#bib0170"><span class="elsevierStyleSup">12</span></a> The addition of a single dose of prandial insulin during the main meal was observed to be an effective strategy for achieving the HbA1c objective.<a class="elsevierStyleCrossRefs" href="#bib0165"><span class="elsevierStyleSup">11,12</span></a></p><p id="par0090" class="elsevierStylePara elsevierViewall">Insulin glargine was selected as the basal insulin due to its extensive use in our setting and for showing an early and sustained benefit with a minimum risk of hypoglycemia, not only in patients poorly controlled with ODD<a class="elsevierStyleCrossRef" href="#bib0175"><span class="elsevierStyleSup">13</span></a> but also in elderly dependent patients (Barthel index<span class="elsevierStyleHsp" style=""></span><<span class="elsevierStyleHsp" style=""></span>20) who are frail and have comorbidities (age-adjusted Charlson comorbidity index, 8<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>2.3).<a class="elsevierStyleCrossRef" href="#bib0180"><span class="elsevierStyleSup">14</span></a> To implement the BP strategy, insulin glulisine was administered before lunch, which is when its greatest efficacy is observed.<a class="elsevierStyleCrossRef" href="#bib0185"><span class="elsevierStyleSup">15</span></a></p><p id="par0095" class="elsevierStylePara elsevierViewall">In this study, a marked reduction in plasma glucose under fasting conditions was observed, while the mean capillary blood glucose values obtained 2<span class="elsevierStyleHsp" style=""></span>h after lunch remained above those recommended by the ADA. Therefore, the improved HbA1c values seemed to be due not only to the addition of the bolus of prandial insulin but also to the fact that during the study period the basal insulin dose continued to be titrated instead of optimizing the rapid insulin dose, perhaps because of an excessive concern about an increase in the incidence of severe hypoglycemia. Elderly patients are especially vulnerable to the onset of hypoglycemia.<a class="elsevierStyleCrossRef" href="#bib0190"><span class="elsevierStyleSup">16</span></a> It is worth noting the results of the ACCORD<a class="elsevierStyleCrossRef" href="#bib0195"><span class="elsevierStyleSup">17</span></a> and VADT studies,<a class="elsevierStyleCrossRef" href="#bib0130"><span class="elsevierStyleSup">4</span></a> which demonstrated that the onset of severe hypoglycemia is an independent predictor of mortality. Consequently, the essential treatment objective for elderly patients with DM2 should be preventing hypoglycemic episodes.<a class="elsevierStyleCrossRef" href="#bib0120"><span class="elsevierStyleSup">2</span></a> Although almost 1 of every 5 patients in our study showed an episode of hypoglycemia, the rate of severe hypoglycemia was very low. These results are consistent with those from the combination of 4 multicenter randomized studies of 711 patients with DM2 poorly controlled with ODD who started BP therapy.<a class="elsevierStyleCrossRef" href="#bib0200"><span class="elsevierStyleSup">18</span></a> The BP regimen helped achieve good glycemic control and a low risk of hypoglycemia or weight gain, regardless of the patient's age or body mass index.<a class="elsevierStyleCrossRef" href="#bib0200"><span class="elsevierStyleSup">18</span></a></p><p id="par0100" class="elsevierStylePara elsevierViewall">An alternative in the therapeutic intensification process for patients with poorly controlled DM2 is the combination of basal insulin and glucagon-like peptide-1 receptor agonists (GLP-1 RAs), which provides a glycemic control similar or superior to that of BP therapy, with a lower risk of hypoglycemia and no weight gain.<a class="elsevierStyleCrossRefs" href="#bib0205"><span class="elsevierStyleSup">19,20</span></a> A study by Rosenstock et al. showed that lixisenatide (a short-acting GLP-1 RA) combined with insulin glargine (with or without ODD) administered to patients with obesity and poorly controlled DM2 was more effective in achieving the glycemic objectives, with a lower rate of hypoglycemic episodes and no weight gain, compared with the addition of insulin glulisine to treatment with insulin glargine (combined or not with ODD).<a class="elsevierStyleCrossRef" href="#bib0215"><span class="elsevierStyleSup">21</span></a> Moreover, the combined therapy of basal insulin and GLP-1 RAs could be a good alternative to intensification with the insulin regimen in elderly patients with DM2 and a high risk of hypoglycemia.<a class="elsevierStyleCrossRef" href="#bib0220"><span class="elsevierStyleSup">22</span></a> Despite the potential of GLP-1 RAs in combination with basal insulin in this patient group, clinical trials that demonstrate this potential are still needed.</p><p id="par0105" class="elsevierStylePara elsevierViewall">This study has a number of limitations. Firstly, this was an observational, retrospective uncontrolled study that did not have a uniform insulin dosage protocol or blood glucose self-monitoring. The hypoglycemic events were self-reported by the patients, which entails a bias of underdiagnosis. Furthermore, the information on the patients’ diabetes education could differ from one center to another, depending on the protocols and dedication employed in the various centers. However, the implementation of this type of study is of utmost importance for understanding the conditions resulting from standard clinical practice.</p><p id="par0110" class="elsevierStylePara elsevierViewall">In conclusion, the results of this research study suggest that the BP insulin strategy (with insulin glargine as basal insulin and insulin glulisine as prandial insulin at the main meal) for patients 65 years or older with DM2 and high cardiovascular risk, following the conditions of standard clinical practice, seems to significantly improve glycemic control while maintaining a low risk of severe hypoglycemia.</p></span><span id="sec0060" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0120">Funding</span><p id="par0115" class="elsevierStylePara elsevierViewall">The study was funded by <span class="elsevierStyleGrantSponsor" id="gs1">Sanofi España</span>.</p></span><span id="sec0065" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0125">Conflicts of interest</span><p id="par0120" class="elsevierStylePara elsevierViewall">G Romero Meliá works for Sanofi. The other authors declare that they have no conflicts of interest regarding this study.</p></span></span>" "textoCompletoSecciones" => array:1 [ "secciones" => array:12 [ 0 => array:3 [ "identificador" => "xres834081" "titulo" => "Abstract" "secciones" => array:4 [ 0 => array:2 [ "identificador" => "abst0005" "titulo" => "Objectives" ] 1 => array:2 [ "identificador" => "abst0010" "titulo" => "Patients and methods" ] 2 => array:2 [ "identificador" => "abst0015" "titulo" => "Results" ] 3 => array:2 [ "identificador" => "abst0020" "titulo" => "Conclusions" ] ] ] 1 => array:2 [ "identificador" => "xpalclavsec830131" "titulo" => "Keywords" ] 2 => array:3 [ "identificador" => "xres834080" "titulo" => "Resumen" "secciones" => array:4 [ 0 => array:2 [ "identificador" => "abst0025" "titulo" => "Objetivos" ] 1 => array:2 [ "identificador" => "abst0030" "titulo" => "Pacientes y métodos" ] 2 => array:2 [ "identificador" => "abst0035" "titulo" => "Resultados" ] 3 => array:2 [ "identificador" => "abst0040" "titulo" => "Conclusiones" ] ] ] 3 => array:2 [ "identificador" => "xpalclavsec830130" "titulo" => "Palabras clave" ] 4 => array:2 [ "identificador" => "sec0005" "titulo" => "Background" ] 5 => array:3 [ "identificador" => "sec0010" "titulo" => "Patients and methods" "secciones" => array:3 [ 0 => array:2 [ "identificador" => "sec0015" "titulo" => "Patient selection" ] 1 => array:2 [ "identificador" => "sec0020" "titulo" => "Patient evaluation" ] 2 => array:2 [ "identificador" => "sec0025" "titulo" => "Statistical analysis" ] ] ] 6 => array:3 [ "identificador" => "sec0030" "titulo" => "Results" "secciones" => array:4 [ 0 => array:2 [ "identificador" => "sec0035" "titulo" => "Patients" ] 1 => array:2 [ "identificador" => "sec0040" "titulo" => "Treatment for diabetes, diabetes education and therapeutic approach" ] 2 => array:2 [ "identificador" => "sec0045" "titulo" => "Changes in glycated hemoglobin and capillary blood glucose" ] 3 => array:2 [ "identificador" => "sec0050" "titulo" => "Adverse events" ] ] ] 7 => array:2 [ "identificador" => "sec0055" "titulo" => "Discussion" ] 8 => array:2 [ "identificador" => "sec0060" "titulo" => "Funding" ] 9 => array:2 [ "identificador" => "sec0065" "titulo" => "Conflicts of interest" ] 10 => array:2 [ "identificador" => "xack280221" "titulo" => "Acknowledgments" ] 11 => array:1 [ "titulo" => "References" ] ] ] "pdfFichero" => "main.pdf" "tienePdf" => true "fechaRecibido" => "2016-10-24" "fechaAceptado" => "2017-02-05" "PalabrasClave" => array:2 [ "en" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Keywords" "identificador" => "xpalclavsec830131" "palabras" => array:5 [ 0 => "Diabetes mellitus" 1 => "Basal insulin" 2 => "Basal-plus" 3 => "Insulinisation" 4 => "Elderly patients" ] ] ] "es" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Palabras clave" "identificador" => "xpalclavsec830130" "palabras" => array:5 [ 0 => "Diabetes mellitus" 1 => "Insulina basal" 2 => "Basal plus" 3 => "Insulinización" 4 => "Pacientes ancianos" ] ] ] ] "tieneResumen" => true "resumen" => array:2 [ "en" => array:3 [ "titulo" => "Abstract" "resumen" => "<span id="abst0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0010">Objectives</span><p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">To assess the safety and efficacy of a basal-plus (BP) regimen with insulin glargine (as basal insulin) and insulin glulisine (as prandial insulin) with the main meal for elderly patients with type 2 diabetes mellitus (DM2) and high cardiovascular risk, following standard clinical practice.</p></span> <span id="abst0010" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0015">Patients and methods</span><p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">An observational, retrospective study was conducted in 21 centers of internal medicine in Spain. The study included patients aged 65 years or older with DM2, undergoing treatment with a BP regimen for 4 to 12 months before inclusion in the study and a diagnosis of cardiovascular disease or high cardiovascular risk. The primary endpoint was the change in glycated hemoglobin (HbA1c) from the introduction of the glulisine to inclusion in the study.</p></span> <span id="abst0015" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0020">Results</span><p id="spar0015" class="elsevierStyleSimplePara elsevierViewall">The study included 198 patients (mean age, 74<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>6.4 years; males, 52%). After at least 4 months of treatment with the BP regimen, started with the addition of glulisine, the mean HbA1c value decreased significantly (9<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>1.5% vs. 7.7<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>1.1%; <span class="elsevierStyleItalic">P</span><span class="elsevierStyleHsp" style=""></span><<span class="elsevierStyleHsp" style=""></span>.001), and almost 24% of the patients reached HbA1c levels of 7.5–8%. Furthermore, blood glucose levels under fasting conditions decreased significantly (190.6<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>73.2<span class="elsevierStyleHsp" style=""></span>mg/dl vs. 138.9<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>38.2<span class="elsevierStyleHsp" style=""></span>mg/dl; <span class="elsevierStyleItalic">P</span><span class="elsevierStyleHsp" style=""></span><<span class="elsevierStyleHsp" style=""></span>.001). A total of 35 patients (17.7%) had some hypoglycaemia during the month prior to the start of the study, and 2 cases (1.01%) of severe hypoglycaemia were detected.</p></span> <span id="abst0020" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0025">Conclusions</span><p id="spar0020" class="elsevierStyleSimplePara elsevierViewall">The BP strategy could significantly improve blood glucose control in patients 65 years of age or older with DM2 and high cardiovascular risk and is associated with a low risk of severe hypoglycaemia.</p></span>" "secciones" => array:4 [ 0 => array:2 [ "identificador" => "abst0005" "titulo" => "Objectives" ] 1 => array:2 [ "identificador" => "abst0010" "titulo" => "Patients and methods" ] 2 => array:2 [ "identificador" => "abst0015" "titulo" => "Results" ] 3 => array:2 [ "identificador" => "abst0020" "titulo" => "Conclusions" ] ] ] "es" => array:3 [ "titulo" => "Resumen" "resumen" => "<span id="abst0025" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0035">Objetivos</span><p id="spar0025" class="elsevierStyleSimplePara elsevierViewall">Evaluar la eficacia y seguridad de una pauta basal plus (BP) con insulina glargina como insulina basal, e insulina glulisina como insulina prandial en la comida principal, en pacientes ancianos con diabetes mellitus tipo 2 (DM2) y alto riesgo cardiovascular, siguiendo la práctica clínica habitual.</p></span> <span id="abst0030" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0040">Pacientes y métodos</span><p id="spar0030" class="elsevierStyleSimplePara elsevierViewall">Estudio observacional, retrospectivo, realizado en 21 centros de medicina interna en España. Se incluyeron sujetos de edad ≥<span class="elsevierStyleHsp" style=""></span>65 años con DM2, en tratamiento con pauta BP durante 4 a 12 meses antes de la inclusión en el estudio, y diagnóstico de enfermedad cardiovascular o elevado riesgo cardiovascular. La variable principal fue el cambio en la hemoglobina glucosilada (HbA1c) desde la introducción de la glulisina hasta la inclusión en el estudio.</p></span> <span id="abst0035" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0045">Resultados</span><p id="spar0035" class="elsevierStyleSimplePara elsevierViewall">Se incluyeron 198 pacientes (edad media de 74<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>6,4 años; hombres: 52%). Tras al menos 4 meses de tratamiento con la pauta BP, iniciada con la adición de glulisina, el valor medio de HbA1c descendió significativamente (9<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>1,5% vs. 7,7<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>1,1%; p<span class="elsevierStyleHsp" style=""></span><<span class="elsevierStyleHsp" style=""></span>0,001) y casi el 24% de los sujetos alcanzaron niveles de HbA1c del 7,5-8%. Asimismo, la glucemia en ayunas descendió significativamente (190,6<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>73,2<span class="elsevierStyleHsp" style=""></span>mg/dl frente a 138,9<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>38,2<span class="elsevierStyleHsp" style=""></span>mg/dl; p<span class="elsevierStyleHsp" style=""></span><<span class="elsevierStyleHsp" style=""></span>0,001). Un total de 35 pacientes (17,7%) presentaron alguna hipoglucemia durante el mes previo al inicio del estudio, y se detectaron 2 casos (1,01%) de hipoglucemia grave.</p></span> <span id="abst0040" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0050">Conclusiones</span><p id="spar0040" class="elsevierStyleSimplePara elsevierViewall">La estrategia BP podría mejorar significativamente el control glucémico en pacientes ≥<span class="elsevierStyleHsp" style=""></span>65 años con DM2 y alto riesgo cardiovascular, y se asocia a un bajo riesgo de hipoglucemia grave.</p></span>" "secciones" => array:4 [ 0 => array:2 [ "identificador" => "abst0025" "titulo" => "Objetivos" ] 1 => array:2 [ "identificador" => "abst0030" "titulo" => "Pacientes y métodos" ] 2 => array:2 [ "identificador" => "abst0035" "titulo" => "Resultados" ] 3 => array:2 [ "identificador" => "abst0040" "titulo" => "Conclusiones" ] ] ] ] "NotaPie" => array:1 [ 0 => array:2 [ "etiqueta" => "☆" "nota" => "<p class="elsevierStyleNotepara" id="npar0005">Please cite this article as: Gómez-Huelgas R, Sabán-Ruiz J, García-Román FJ, Quintela-Fernández N, Seguí-Ripoll JM, Bonilla-Hernández MV, et al. Eficacia y seguridad de una pauta basal plus con insulina glargina e insulina glulisina en pacientes ancianos de alto riesgo cardiovascular con diabetes mellitus tipo 2. Rev Clin Esp. 2017;217:201–206.</p>" ] ] "multimedia" => array:3 [ 0 => array:7 [ "identificador" => "fig0005" "etiqueta" => "Figure 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 1190 "Ancho" => 1658 "Tamanyo" => 107902 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0045" class="elsevierStyleSimplePara elsevierViewall">Average of the 3 self-analysis profiles of capillary blood glucose.</p>" ] ] 1 => array:8 [ "identificador" => "tbl0005" "etiqueta" => "Table 1" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at1" "detalle" => "Table " "rol" => "short" ] ] "tabla" => array:2 [ "leyenda" => "<p id="spar0055" class="elsevierStyleSimplePara elsevierViewall"><span class="elsevierStyleItalic">Abbreviations</span>: BMI, body mass index; HbA1c, glycated hemoglobin; SD, standard deviation.</p>" "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Characteristics \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Values \t\t\t\t\t\t\n \t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleItalic">Mean age, years</span><span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">SD</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">74.0<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>6.4 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleItalic">Men, n (%)</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">103 (52) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleItalic">Mean weight, kg</span><span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">SD</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">79.9<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>13.3 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleItalic">Mean BMI, kg/m</span><span class="elsevierStyleSup"><span class="elsevierStyleItalic">2</span></span><span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">SD</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">29.7<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>5 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleItalic">Mean time from insulinization to study inclusion, months</span><span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">TD</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">23.4<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>29.5 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " colspan="2" align="left" valign="top"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td" title="table-entry " colspan="2" align="left" valign="top"><span class="elsevierStyleItalic">Mean duration of diabetes, years</span><span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">SD</span></td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Patients with HbA1c <7.0% \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">9.2<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>8.6 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Patients with HbA1c >7.0% \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">14.0<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>8.8 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleItalic">Smokers, n (%)</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">46 (23.4) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleItalic">Cardiovascular disease, n (%)</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">150 (77.3) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Ischemic heart disease \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">80 (40.4) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Stroke \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">52 (26.3) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Peripheral arterial disease \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">53 (26.8) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Other \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">11 (5.6) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " colspan="2" align="left" valign="top"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td" title="table-entry " colspan="2" align="left" valign="top"><span class="elsevierStyleItalic">Comorbidities, n (%)</span></td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Hypertension \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">180 (90.9) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Dyslipidemia \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">158 (79.8) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Obesity \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">94 (47.5) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Other \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">11 (7.3) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>None \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">5 (2.5) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " colspan="2" align="left" valign="top"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td" title="table-entry " colspan="2" align="left" valign="top"><span class="elsevierStyleItalic">Risk factors, n (%)</span></td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Microalbuminuria \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">79 (39.9) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Macroalbuminuria \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">7 (3.5) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Renal failure \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">42 (21.1) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Neuropathy \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">27 (13.6) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Retinopathy \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">45 (22.7) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Atrial fibrillation \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">12 (6.1) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Heart failure \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">23 (11.6) \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab1406589.png" ] ] ] ] "descripcion" => array:1 [ "en" => "<p id="spar0050" class="elsevierStyleSimplePara elsevierViewall">Baseline characteristics of the study population (<span class="elsevierStyleItalic">N</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>198).</p>" ] ] 2 => array:8 [ "identificador" => "tbl0010" "etiqueta" => "Table 2" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at2" "detalle" => "Table " "rol" => "short" ] ] "tabla" => array:1 [ "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="table-head " align="" valign="top" scope="col"> \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col">Daytime \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col">Nocturnal \t\t\t\t\t\t\n \t\t\t\t</th></tr><tr title="table-row"><th class="td" title="table-head " align="" valign="top" scope="col" style="border-bottom: 2px solid black"> \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black"><span class="elsevierStyleItalic">n</span> \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black"><span class="elsevierStyleItalic">n</span> \t\t\t\t\t\t\n \t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Symptomatic \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">22 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">8 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Asymptomatic \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">7 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">4 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Nonsevere \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">15 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">4 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Severe \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">1 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">1 \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab1406588.png" ] ] ] ] "descripcion" => array:1 [ "en" => "<p id="spar0060" class="elsevierStyleSimplePara elsevierViewall">Classification of hypoglycemia events recorded during the study.</p>" ] ] ] "bibliografia" => array:2 [ "titulo" => "References" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bibs0005" "bibliografiaReferencia" => array:22 [ 0 => array:3 [ "identificador" => "bib0115" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD)" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "L. Ryden" 1 => "P.J. Grant" 2 => "S.D. Anker" 3 => "C. Berne" 4 => "F. Cosentino" 5 => "N. Danchin" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1093/eurheartj/eht108" "Revista" => array:6 [ "tituloSerie" => "Eur Heart J" "fecha" => "2013" "volumen" => "34" "paginaInicial" => "3035" "paginaFinal" => "3087" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/23996285" "web" => "Medline" ] ] ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib0120" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Tratamiento de la diabetes tipo 2 en el anciano" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "R. Gomez Huelgas" 1 => "J. Diez-Espino" 2 => "F. Formiga" 3 => "J. Lafita Tejedor" 4 => "L. Rodriguez Manas" 5 => "E. Gonzalez-Sarmiento" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Med Clin (Barc)" "fecha" => "2013" "volumen" => "140" "paginaInicial" => "e1" "paginaFinal" => "e12" ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib0125" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Diabetes mellitus: prevalence and effect of morbidities in the oldest old. The Octabaix study" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "A. Ferrer" 1 => "G. Padros" 2 => "F. Formiga" 3 => "S. Rojas-Farreras" 4 => "J.M. Perez" 5 => "R. Pujol" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/j.1532-5415.2011.03835.x" "Revista" => array:6 [ "tituloSerie" => "J Am Geriatr Soc" "fecha" => "2012" "volumen" => "60" "paginaInicial" => "462" "paginaFinal" => "467" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/22315989" "web" => "Medline" ] ] ] ] ] ] ] ] 3 => array:3 [ "identificador" => "bib0130" "etiqueta" => "4" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Glucose control and vascular complications in veterans with type 2 diabetes" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "W. Duckworth" 1 => "C. Abraira" 2 => "T. Moritz" 3 => "D. Reda" 4 => "N. Emanuele" 5 => "P.D. Reaven" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1056/NEJMoa0808431" "Revista" => array:6 [ "tituloSerie" => "N Engl J Med" "fecha" => "2009" "volumen" => "360" "paginaInicial" => "129" "paginaFinal" => "139" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19092145" "web" => "Medline" ] ] ] ] ] ] ] ] 4 => array:3 [ "identificador" => "bib0135" "etiqueta" => "5" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: An analysis of the ACCORD randomised trial" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "F. Ismail-Beigi" 1 => "T. Craven" 2 => "M.A. Banerji" 3 => "J. Basile" 4 => "J. Calles" 5 => "R.M. Cohen" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/S0140-6736(10)60576-4" "Revista" => array:6 [ "tituloSerie" => "Lancet" "fecha" => "2010" "volumen" => "376" "paginaInicial" => "419" "paginaFinal" => "430" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/20594588" "web" => "Medline" ] ] ] ] ] ] ] ] 5 => array:3 [ "identificador" => "bib0140" "etiqueta" => "6" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "A. Patel" 1 => "S. MacMahon" 2 => "J. Chalmers" 3 => "B. Neal" 4 => "L. Billot" 5 => "M. Woodward" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1056/NEJMoa0802987" "Revista" => array:6 [ "tituloSerie" => "N Engl J Med" "fecha" => "2008" "volumen" => "358" "paginaInicial" => "2560" "paginaFinal" => "2572" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18539916" "web" => "Medline" ] ] ] ] ] ] ] ] 6 => array:3 [ "identificador" => "bib0145" "etiqueta" => "7" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Individualised treatment targets for elderly patients with type 2 diabetes using vildagliptin add-on or lone therapy (INTERVAL): a 24 week, randomised, double-blind, placebo-controlled study" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "W.D. Strain" 1 => "V. Lukashevich" 2 => "W. Kothny" 3 => "M.J. Hoellinger" 4 => "P.M. Paldanius" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/S0140-6736(13)60995-2" "Revista" => array:6 [ "tituloSerie" => "Lancet" "fecha" => "2013" "volumen" => "382" "paginaInicial" => "409" "paginaFinal" => "416" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/23706759" "web" => "Medline" ] ] ] ] ] ] ] ] 7 => array:3 [ "identificador" => "bib0150" "etiqueta" => "8" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "European Diabetes Working Party for Older People 2011 clinical guidelines for type 2 diabetes mellitus. Executive summary" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "A.J. Sinclair" 1 => "G. Paolisso" 2 => "M. Castro" 3 => "I. Bourdel-Marchasson" 4 => "R. Gadsby" 5 => "L. Rodriguez Manas" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/S1262-3636(11)70962-4" "Revista" => array:7 [ "tituloSerie" => "Diabetes Metab" "fecha" => "2011" "volumen" => "37" "numero" => "Suppl. 3" "paginaInicial" => "S27" "paginaFinal" => "S38" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/22183418" "web" => "Medline" ] ] ] ] ] ] ] ] 8 => array:3 [ "identificador" => "bib0155" "etiqueta" => "9" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Management of hyperglycemia in type 2 diabetes: A patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "S.E. Inzucchi" 1 => "R.M. Bergenstal" 2 => "J.B. Buse" 3 => "M. Diamant" 4 => "E. Ferrannini" 5 => "M. Nauck" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.2337/dc12-0413" "Revista" => array:6 [ "tituloSerie" => "Diabetes Care" "fecha" => "2012" "volumen" => "35" "paginaInicial" => "1364" "paginaFinal" => "1379" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/22517736" "web" => "Medline" ] ] ] ] ] ] ] ] 9 => array:3 [ "identificador" => "bib0160" "etiqueta" => "10" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "A call for action in diabetes care for older people" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "L. Rodriguez-Manas" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/j.1464-5491.2011.03335.x" "Revista" => array:6 [ "tituloSerie" => "Diabet Med" "fecha" => "2011" "volumen" => "28" "paginaInicial" => "757" "paginaFinal" => "758" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21671999" "web" => "Medline" ] ] ] ] ] ] ] ] 10 => array:3 [ "identificador" => "bib0165" "etiqueta" => "11" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Effects of initiation and titration of a single pre-prandial dose of insulin glulisine while continuing titrated insulin glargine in type 2 diabetes: a 6-month ‘proof-of-concept’ study" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "D.R. Owens" 1 => "S.D. Luzio" 2 => "C. Sert-Langeron" 3 => "M.C. Riddle" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/j.1463-1326.2011.01459.x" "Revista" => array:6 [ "tituloSerie" => "Diabetes Obes Metab" "fecha" => "2011" "volumen" => "13" "paginaInicial" => "1020" "paginaFinal" => "1027" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21679291" "web" => "Medline" ] ] ] ] ] ] ] ] 11 => array:3 [ "identificador" => "bib0170" "etiqueta" => "12" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Introducing a simplified approach to insulin therapy in type 2 diabetes: a comparison of two single-dose regimens of insulin glulisine plus insulin glargine and oral antidiabetic drugs" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "M.R. Lankisch" 1 => "K.C. Ferlinz" 2 => "J.L. Leahy" 3 => "W.A. Scherbaum" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/j.1463-1326.2008.00967.x" "Revista" => array:6 [ "tituloSerie" => "Diabetes Obes Metab" "fecha" => "2008" "volumen" => "10" "paginaInicial" => "1178" "paginaFinal" => "1185" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19040645" "web" => "Medline" ] ] ] ] ] ] ] ] 12 => array:3 [ "identificador" => "bib0175" "etiqueta" => "13" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Efficacy and safety of basal insulin glargine 12 and 24 weeks after initiation in persons with type 2 diabetes: a pooled analysis of data from treatment arms of 15 treat-to-target randomised controlled trials" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "D.R. Owens" 1 => "L. Traylor" 2 => "M.P. Dain" 3 => "W. Landgraf" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.diabres.2014.08.003" "Revista" => array:6 [ "tituloSerie" => "Diabetes Res Clin Pract" "fecha" => "2014" "volumen" => "106" "paginaInicial" => "264" "paginaFinal" => "274" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/25195151" "web" => "Medline" ] ] ] ] ] ] ] ] 13 => array:3 [ "identificador" => "bib0180" "etiqueta" => "14" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Treatment management and glycaemic control in a sample of 60 frail elderly diabetics with comorbidities. A retrospective chart review" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "J.M. Segui Ripoll" 1 => "P. Esteve Atienzar" 2 => "J.C. Lopez Corbalan" 3 => "P. Roig Rico" 4 => "M.J. Navarro Navarro" 5 => "J. Merino Sanchez" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.ejim.2015.04.017" "Revista" => array:6 [ "tituloSerie" => "Eur J Intern Med" "fecha" => "2015" "volumen" => "26" "paginaInicial" => "456" "paginaFinal" => "457" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/25952674" "web" => "Medline" ] ] ] ] ] ] ] ] 14 => array:3 [ "identificador" => "bib0185" "etiqueta" => "15" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Advantage of premeal-injected insulin glulisine compared with regular human insulin in subjects with type 1 diabetes" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "K. Rave" 1 => "O. Klein" 2 => "A.D. Frick" 3 => "R.H. Becker" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.2337/dc06-0383" "Revista" => array:6 [ "tituloSerie" => "Diabetes Care" "fecha" => "2006" "volumen" => "29" "paginaInicial" => "1812" "paginaFinal" => "1817" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/16873785" "web" => "Medline" ] ] ] ] ] ] ] ] 15 => array:3 [ "identificador" => "bib0190" "etiqueta" => "16" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Hypoglycemia unawareness in older compared with middle-aged patients with type 2 diabetes" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "J.P. Bremer" 1 => "K. Jauch-Chara" 2 => "M. Hallschmid" 3 => "S. Schmid" 4 => "B. Schultes" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.2337/dc09-0114" "Revista" => array:6 [ "tituloSerie" => "Diabetes Care" "fecha" => "2009" "volumen" => "32" "paginaInicial" => "1513" "paginaFinal" => "1517" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19487634" "web" => "Medline" ] ] ] ] ] ] ] ] 16 => array:3 [ "identificador" => "bib0195" "etiqueta" => "17" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Effects of intensive glucose lowering in type 2 diabetes" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "H.C. Gerstein" 1 => "M.E. Miller" 2 => "R.P. Byington" 3 => "D.C. Goff Jr." 4 => "J.T. Bigger" 5 => "J.B. Buse" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1056/NEJMoa0802743" "Revista" => array:6 [ "tituloSerie" => "N Engl J Med" "fecha" => "2008" "volumen" => "358" "paginaInicial" => "2545" "paginaFinal" => "2559" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18539917" "web" => "Medline" ] ] ] ] ] ] ] ] 17 => array:3 [ "identificador" => "bib0200" "etiqueta" => "18" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Use of a basal-plus insulin regimen in persons with type 2 diabetes stratified by age and body mass index: a pooled analysis of four clinical trials" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "M.R. Lankisch" 1 => "S. del Prato" 2 => "M.P. Dain" 3 => "P. Mullins" 4 => "D.R. Owens" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.pcd.2015.05.003" "Revista" => array:6 [ "tituloSerie" => "Prim Care Diabetes" "fecha" => "2016" "volumen" => "10" "paginaInicial" => "51" "paginaFinal" => "59" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/26150328" "web" => "Medline" ] ] ] ] ] ] ] ] 18 => array:3 [ "identificador" => "bib0205" "etiqueta" => "19" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The role of basal insulin and glucagon-like peptide-1 agonists in the therapeutic management of type 2 diabetes – a comprehensive review" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "S.K. Garg" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1089/dia.2009.0127" "Revista" => array:6 [ "tituloSerie" => "Diabetes Technol Ther" "fecha" => "2010" "volumen" => "12" "paginaInicial" => "11" "paginaFinal" => "24" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/20082581" "web" => "Medline" ] ] ] ] ] ] ] ] 19 => array:3 [ "identificador" => "bib0210" "etiqueta" => "20" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Glucagon-like peptide-1 analog and insulin combination therapy in the management of adults with type 2 diabetes mellitus" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "M. Tzefos" 1 => "J.L. Olin" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1345/aph.1P047" "Revista" => array:6 [ "tituloSerie" => "Ann Pharmacother" "fecha" => "2010" "volumen" => "44" "paginaInicial" => "1294" "paginaFinal" => "1300" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/20530705" "web" => "Medline" ] ] ] ] ] ] ] ] 20 => array:3 [ "identificador" => "bib0215" "etiqueta" => "21" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Prandial options to advance basal insulin llargine therapy: Testing lixisenatide plus basal insulin versus insulin glulisine either as basal-plus or basal-bolus in type 2 diabetes: the GetGoal Duo-2 Trial" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "J. Rosenstock" 1 => "B. Guerci" 2 => "M. Hanefeld" 3 => "S. Gentile" 4 => "R. Aronson" 5 => "F.J. Tinahones" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.2337/dc16-0014" "Revista" => array:6 [ "tituloSerie" => "Diabetes Care" "fecha" => "2016" "volumen" => "39" "paginaInicial" => "1318" "paginaFinal" => "1328" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/27222510" "web" => "Medline" ] ] ] ] ] ] ] ] 21 => array:3 [ "identificador" => "bib0220" "etiqueta" => "22" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Basal insulin combined incretin mimetic therapy with glucagon-like protein 1 receptor agonists as an upcoming option in the treatment of type 2 diabetes: a practical guide to decision making" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "G.H. Scholz" 1 => "H. Fleischmann" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1177/2042018814556099" "Revista" => array:6 [ "tituloSerie" => "Ther Adv Endocrinol Metab" "fecha" => "2014" "volumen" => "5" "paginaInicial" => "95" "paginaFinal" => "123" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/25419451" "web" => "Medline" ] ] ] ] ] ] ] ] ] ] ] ] "agradecimientos" => array:1 [ 0 => array:4 [ "identificador" => "xack280221" "titulo" => "Acknowledgments" "texto" => "<p id="par0125" class="elsevierStylePara elsevierViewall">The authors of the study would like to thank Ana López Ballesteros and Antonio Torres Ruiz of Dynamic SL for their contribution to the medical drafting of the manuscript.</p>" "vista" => "all" ] ] ] "idiomaDefecto" => "en" "url" => "/22548874/0000021700000004/v1_201704280917/S2254887417300334/v1_201704280917/en/main.assets" "Apartado" => array:4 [ "identificador" => "1901" "tipo" => "SECCION" "en" => array:2 [ "titulo" => "Original Articles" "idiomaDefecto" => true ] "idiomaDefecto" => "en" ] "PDF" => "https://static.elsevier.es/multimedia/22548874/0000021700000004/v1_201704280917/S2254887417300334/v1_201704280917/en/main.pdf?idApp=WRCEE&text.app=https://revclinesp.es/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2254887417300334?idApp=WRCEE" ]
